I have colon cancer. Can genome testing reveal cancer risk?

Hello,

Welcome to icliniq.com.

Thank you for reaching out. I understand that a recent colon cancer diagnosis can feel overwhelming, and it is natural to have questions about treatment and family risk. I will explain cancer genome testing, its usefulness, limitations, and the next steps.

Cancer genome testing analyzes the DNA (deoxyribonucleic acid) of your tumor to identify mutations that can guide targeted therapy.

KRAS and NRAS mutations help predict response to EGFR-targeted therapy, BRAF mutations guide treatment intensity, and MSI-H or dMMR status may indicate potential benefit from immunotherapy.

Rare mutations such as NTRK and HER2 (human epidermal growth factor receptor 2) may open options for newer targeted therapies. Cancer genome testing can also provide prognostic information.

Regarding inherited risk, tumor testing may suggest hereditary cancer syndromes such as Lynch syndrome; however, germline testing from blood or saliva is required to confirm family risk.

The probable cause is colon cancer. Investigations to be done include:

1. Tumor genomic profiling for KRAS, NRAS, BRAF, MSI-H/dMMR, HER2, and NTRK.

2. Germline testing using blood or saliva for hereditary cancer risk, such as Lynch syndrome.

3. Routine laboratory tests, including CBC (complete blood count), liver and kidney function tests, and CEA (carcinoembryonic antigen) tumor marker.

4. Imaging studies such as CT (computed tomography) or MRI (magnetic resonance imaging) of the abdomen and pelvis, with PET if needed.

5. Colonoscopy with biopsy to confirm the diagnosis.

The differential diagnosis includes

1. Benign colorectal polyps.

2. Inflammatory bowel disease.

3. Colorectal lymphoma.

4. Diverticular disease with complications.

5. Metastatic tumors to the colon.

The probable diagnosis is colon cancer.

The treatment plan includes

1. Surgery to remove the tumor and evaluate the lymph nodes.

2. Chemotherapy as adjuvant or neoadjuvant therapy based on disease stage.

3. Targeted therapy or immunotherapy guided by genomic profiling results such as KRAS, BRAF, MSI-H, HER2, and NTRK status.

Follow-up involves regular CEA testing, imaging, and colonoscopy.

Supportive care includes nutritional support, symptom management, and psychological support.

Preventive measures include

1. Regular screening with colonoscopy or stool tests.

2. Maintaining a high-fiber and healthy diet while limiting red and processed meat.

3. Maintaining a healthy weight with regular exercise.

4. Avoiding smoking and limiting alcohol intake.

5. Managing chronic gastrointestinal conditions.

6. Seeking family genetic counseling if a hereditary risk is identified.

Regular follow-up with your oncologist is essential to monitor progress. This includes blood tests, periodic imaging with CT (computed tomography), MRI (magnetic resonance imaging), or PET (positron-emission testing), and review of colonoscopy findings. During these visits, symptoms, treatment response, and genomic testing results can be assessed.

Video consultations are an effective way to discuss reports, adjust therapy, and receive ongoing nutritional, psychological, and supportive care while minimizing travel and ensuring timely management.

I hope this helps.

Thank you.